1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Another IPF Drug Failure As Galecto Therapy Suffers Mid-Stage Flop

Firm To Focus On Liver After Lung Miss

 
• By Kevin Grogan

Galecto’s decision to discontinue its idiopathic pulmonary fibrosis candidate after disappointing Phase IIb results represents the latest in a number of mid/late-stage failures to treat the disease.

Neon Light Sign Lungs Icon
• Source: Shutterstock

Galecto Inc. has become the latest company to fail at developing a new therapy for idiopathic pulmonary fibrosis (IPF) and has decided to concentrate its research efforts on severe liver diseases.

The switch in focus follows topline results from the Boston-based biotech's Phase IIb GALACTIC-1 trial evaluating GBO139, an inhaled galectin-3 inhibitor in 173 IPF patients who had not previously received the two standard-of-care treatments for the disease - Roche Holding AG’s Esbriet (pirfenidone) and Boehringer Ingelheim GmbH’s Ofev (nintedanib)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.